Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2013-01-15

Sodium oxybate intolerance associated with familial serum acylcarnitine elevation.

Jon Berner

Index: J. Clin. Sleep Med. 9(1) , 71-2, (2013)

Full Text: HTML

Abstract

Our case describes clinical features of two families defined by joint phenotypes: sodium oxybate intolerance and elevated serum acylcarnitines. Oxybate intolerance variably presents as either cervical dystonia or sleep-related eating disorder. Our objective is to identify biological markers which predict a poor response to sodium oxybate as a treatment for disturbed sleep. Familial inheritance pattern, genotype analysis, multiorgan system involvement, and response to treatment suggest the presence of a secondary cause of fatty oxidation defect, i.e., mitochondrial disorder. Our case report supports the possible conclusion that variance in human mitochondrial metabolism may affect sodium oxybate tolerability.


Related Compounds

Related Articles:

An improved design of water-soluble propofol prodrugs characterized by rapid onset of action.

2014-04-01

[Anesth. Analg. 118(4) , 745-54, (2014)]

Treatment of alcohol dependence: recent progress and reduction of consumption.

2014-12-01

[Minerva Med. 105(6) , 447-66, (2014)]

Discriminative stimulus effects of the GABAB receptor-positive modulator rac-BHFF: comparison with GABAB receptor agonists and drugs of abuse.

2013-03-01

[J. Pharmacol. Exp. Ther. 344(3) , 553-60, (2013)]

Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.

2013-04-01

[J. Pharmacol. Exp. Ther. 345(1) , 102-10, (2013)]

The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.

2012-07-01

[Clin. Toxicol. (Phila.) 50(6) , 458-70, (2012)]

More Articles...